Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulmonary gas exchange

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Pulmonary gas exchange. Displaying page 1 of 1.
    EudraCT Number: 2005-001525-28 Sponsor Protocol Number: ICL-INONAC1 Start Date*: 2006-03-24
    Sponsor Name:Imperial College London
    Full Title: INFLUENCE OF THE ANTIOXIDANT N-ACETYLCYSTEINE ON INHALED NITRIC OXIDE INDUCED PULMONARY RESPONSES FOLLOWING HUMAN LUNG ISCHAEMIA-REPERFUSION INJURY
    Medical condition: heart-lung transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003725-22 Sponsor Protocol Number: KKS-306 Start Date*: 2023-04-20
    Sponsor Name:Justus-Liebig-University Gießen
    Full Title: Acute effect of iloprost (Ventavis®) inhalation in patients with exercise-induced pulmonary hypertension after a COVID-19 infection
    Medical condition: Exercise-induced pulmonary hypertension after a COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    24.1 100000004862 10085867 Post-COVID-19 syndrome LLT
    24.1 100000004862 10085868 Long COVID-19 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023366-49 Sponsor Protocol Number: Bosentan for HPS Start Date*: 2011-07-22
    Sponsor Name:Med. Univ. Wien, Univ. Klinikum für Interne Medizin III
    Full Title: Bosentan for treatment ofhepatopulmonary syndrome in patients with liver cirrhosis - a prospective double blind randomized controlled clinical study
    Medical condition: HPS is by far the most frequent respiratory complication of cirrhosis leading to significantly increased mortality. The only therapeutic option is liver transplantation. Many patients with HPS who ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004461-13 Sponsor Protocol Number: CQVA149A2325 Start Date*: 2016-04-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002038-37 Sponsor Protocol Number: 5.0 Start Date*: 2012-03-06
    Sponsor Name:University of Oxford
    Full Title: Hyperpolarised xenon magnetic resonance imaging (Xe-129 MRI) lung imaging in COPD
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013226-17 Sponsor Protocol Number: AustrNHMRVID436677 Start Date*: 2009-09-29
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: The ENIGMA-II Trial. Nitrous oxide anaesthesia and cardiac morbidity after major surgery: a randomised controlled trial
    Medical condition: The study investigates standard anaesthesia for surgery. There is no single specific 'disease' rather there is a population of patients requiring anaesthesia to permit surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002324-15 Sponsor Protocol Number: P01092 Start Date*: 2007-09-04
    Sponsor Name:University of East Anglia
    Full Title: The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia
    Medical condition: Idiopathic Interstitial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022619 Interstitial pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004919-39 Sponsor Protocol Number: ND-L02-s0201-005 Start Date*: 2018-11-20
    Sponsor Name:Nitto Denko Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024585-22 Sponsor Protocol Number: WILK3 Start Date*: 2011-03-25
    Sponsor Name:Imperial College Academic Healthsciences Centre
    Full Title: What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?
    Medical condition: Idiopathic or familial pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005260-15 Sponsor Protocol Number: FPCLI002 Start Date*: 2016-02-10
    Sponsor Name:Faron Pharmaceuticals Ltd
    Full Title: A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera...
    Medical condition: Adult patients diagnosed with moderate or severe Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003083 ARDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001281-86 Sponsor Protocol Number: CNTO888PUL2001 Start Date*: 2009-01-14
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in ...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001109-15 Sponsor Protocol Number: BIOTOB Start Date*: 2015-12-15
    Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE
    Full Title: A Phase III clinical trial randomized and blinded on the use of inhaled tobramycin compared with placebo in patients undergoing mechanical ventilation and colonized by Gram negative bacteria for ef...
    Medical condition: critically ill patients undergoing mechanical ventilation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10066821 Mechanical ventilation complication PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006130-12 Sponsor Protocol Number: Asperum Start Date*: 2021-03-25
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Multicenter randomized, double-blind, placebo-controlled, clinical trial of Acetylsalicylic acid in the prevention of severe COVID-19 pneumonia in hospitalised patients (Asperum)
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10076502 Viral pneumonitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002322-85 Sponsor Protocol Number: KAN0006 Start Date*: 2020-07-02
    Sponsor Name:Kancera AB
    Full Title: KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics.
    Medical condition: Acute respiratory distress syndrome (ARDS) in COVID-19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000827-13 Sponsor Protocol Number: A5951001 Start Date*: 2007-11-26
    Sponsor Name:Pfizer Pharmaceutical Group
    Full Title: LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
    Medical condition: MRSA Infection - Nosocomical Pneumenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003633-42 Sponsor Protocol Number: RBHIPF004 Start Date*: 2013-10-18
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
    Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10027754 Mixed connective tissue disease PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039710 Scleroderma PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036102 Polymyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000516-37 Sponsor Protocol Number: TS-020DESE Start Date*: 2021-03-04
    Sponsor Name:TurnSole Biologics Llc
    Full Title: A Phase I/II open-label study for Azacitidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20–50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients ...
    Medical condition: COVID-19 patients with confirmed sever viral infection of SARS-COV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047461 Viral infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 13:09:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA